Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
September 25, 2023
A new study urges CARe when considering multispecific CAR-T cell therapy
From the Riddell Lab, Translational Science and Therapeutics Division
CAR T-cell therapy is the leading edge of care for post-transplant lymphoproliferative disorder
A Fred Hutch patient became the 17th in the world to receive this pioneering treatment
Boost and attack approach for metastatic prostate cancer therapy!
From the Lee Lab, Human Biology and Clinical Research Divisions, Cancer Consortium
Flipping out to develop an intracellular protein-targeting CAR T cell therapy to treat AML
From the Meshinchi Lab, Clinical Research and Translational Science and Therapeutics Divisions.
Improving immunotherapy for advanced prostate cancer
Preclinical work identifies better target and recruits more immune cells to make CAR-T therapy work for solid tumors
Work smarter not harder: Leveraging cancer immunotherapies to improve organ transplantation
From the Hill Group, Vaccine and Infectious Disease and Clinical Research Divisions
Localized delivery of CAR T cells to treat children with brain tumors
From the Paulovich Lab, Translational Science and Therapeutics Division and Nicholas Vitanza Seattle Children’s Research Institute
Dr. Fred Appelbaum receives Lifetime Achievement award
Medical pioneer and longtime Fred Hutch leader honored by American Society for Transplantation and Cellular Therapy
How blood cancer research might help organ transplant patients
Fred Hutch study suggests certain immune cells are source of antibodies that attack donated organs
Dr. Phil Greenberg becomes president-elect of American Association for Cancer Research
Immunologist looks ahead to international leadership role
Red Light, Green Light: Precise cell targeting with Co-LOCKR
From the Baker, Riddell, and Pun Labs, Cancer Basic Biology, Cancer Consortium
Potential strategies for mitigating CD19 CAR T-cell associated toxicities
From the Gauthier Group, Clinical Research Division
Hopes and predictions for 2022
Hutch researchers look ahead to an increase in cancer screening, improved vaccines and greater trust in science
Vaccination after CAR-T-cell therapy
From the Hill group, Vaccine and Infectious Disease Division and the UW/Fred Hutch Cancer Consortium